Cambiar Aggressive Value ETFCAMX
CAMX
0
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
0.55% less ownership
Funds ownership: 9.56% [Q3] → 9.01% (-0.55%) [Q4]
9% less capital invested
Capital invested by funds: $5.66M [Q3] → $5.17M (-$486K) [Q4]
11% less funds holding
Funds holding: 9 [Q3] → 8 (-1) [Q4]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Research analyst outlook
We haven’t received any recent analyst ratings for CAMX.
Financial journalist opinion
Negative
ETF Trends
1 week ago
Delta Earnings Showcase 2025 Worries & Active ETF Opportunities
While many market sectors are being troubled by macroeconomic uncertainty, the travel sector may very well have it the worst. Given the rise in inflationary pressures and recession risks, it could be difficult to justify travel expenditures at the moment.
Neutral
PRNewsWire
9 months ago
Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients
Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1 ≤ 1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom and quality of life scores vs baseline Study results reinforce previously reported interim results from ACROINNOVA 21 LUND, Sweden , July 15, 2024 /PRNewswire/ -- Camurus (NASDAQ: CAMX) (STO: CAMX) today announced positive, final, topline results from the 52-week Phase 3 open-label ACROINNOVA 2 (NCT04125836) study, which evaluated safety and efficacy of the company's once-monthly octreotide subcutaneous (SC) depot (CAM2029). The study included a total of 135 patients with acromegaly who were biochemically controlled (IGF-1≤1xULN) or uncontrolled on stable doses of standard-of-care (SoC) with first generation somatostatin ligands (SRL) at screening; of these, 81 were new to study patients and 54 were roll-over patients from 24-week randomized treatment with octreotide SC depot or placebo (ACROINNOVA 1).
Charts implemented using Lightweight Charts™